Induction of immune tolerance
AssigneeGenzyme Corporation
InventorJohn M. Williams
Life of this patent
Estimating the term…
Abstract
Methods of inducing immune tolerance by administering an immunosuppressive agent and a compound represented by Formula (I) are disclosed: 1 Additionally methods of suppressing an immune response by administering an immunosuppressive agent and a compound represented by Formula (I) are disclosed. Further disclosed are methods for treating autoimmune diseases by administering an immunosuppressive agent and a compound represented by Formula (I). The variables of Formula (I) are described herein.
Claims20
A method of inhibiting rejection of a transplanted organ, tissue or cell in a mammal, the method comprising the step of administering to the recipient mammal an effective amount of an immunosuppressive agent and an effective amount of a compound represented by the following structural formula:
- 6
- or a physiological salt thereof, wherein:
- R1 is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group;
- R2 is an optionally substituted aralkyl group or an alkyl group substituted with —NR5R6;
- R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
- R4 a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
- and
- R5 and R6 are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R5 and R6 taken together with the nitrogen to which they are attached are a non-aromatic heterocyclic group.
A method of inhibiting rejection of a transplanted organ, tissue or cell in a mammal, the method comprising the step of administering to the recipient mammal an effective amount of an anti CD40L monoclonal antibody or rapamycin and an effective amount of a compound represented by the following structural formula:
- 8
- or a pharmaceutically acceptable salt of the compound.
A composition comprising an immunsuppressive agent and a compound represented by the following structural formula:
- 9
- or a physiological salt thereof, wherein:
- R1 is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group;
- R2 is an optionally substituted aralkyl group or an alkyl group substituted with —NR5R6;
- R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
- R4 a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
- and
- R5 and R6 are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R5 and R6 taken together with the nitrogen to which they are attached are a non-aromatic heterocyclic group.
A composition comprising an anti CD40L monoclonal antibody or repamycin and a compound represented by the following structural formula:
- 10
- or a pharmaceutically acceptable salt of the compound.
- 11
- R11 is —H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;
- R12 is alkyl substituted with NR15R16, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;
- R13 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl;
- and
- each R14 is independently, —H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;
- R15 and R16 are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or R15 and R16 together with the nitrogen to which they are attached are a heterocycloalkyl.
A method of inhibiting rejection of a transplanted organ, tissue or cell in a mammal, the method comprising the step of administering to the recipient mammal an effective amount of an immunosuppressive agent and an effective amount of a compound represented by the following structural formula:
- 12
- R11 is —H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;
- R12 is alkyl substituted with NR15R16, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;
- R13 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl;
- and
- each R14 is independently, —H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;
- R15 and R16 are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or R15 and R16 together with the nitrogen to which they are attached are a heterocycloalkyl.
Dependencies are inferred from the claim text.